Home › Plexiform Neurofibroma › Maryland
Plexiform Neurofibroma clinical trials in Maryland
6 studies for Plexiform Neurofibroma are looking for participants at sites in Maryland.
Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational studyHealthy volunteers welcome
Ages 5 and older · All sexes · Updated Sep 22, 2026 · NCT02544022Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
Ages 3 to 120 · All sexes · Updated Sep 2, 2026 · NCT06222203Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 1
Ages 3 to 35 · All sexes · Updated Aug 24, 2026 · NCT02390752A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1
- Johns Hopkins Hospital, Baltimore
RecruitingPhase 2
Ages 12 and older · All sexes · Updated Jul 29, 2026 · NCT06541847A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1)
- National Institutes of Health Clinical Center, Bethesda
Recruiting
Ages 1 to 120 · All sexes · Updated Jun 9, 2026 · NCT06507748Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1
- Johns Hopkins University, Baltimore
- National Cancer Institute/ National Institutes of Health, Bethesda
RecruitingPhase 2
Ages 1 to 8 · All sexes · Updated May 29, 2026 · NCT06188741From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.